Literature DB >> 10482597

Decreased processivity of human immunodeficiency virus type 1 reverse transcriptase (RT) containing didanosine-selected mutation Leu74Val: a comparative analysis of RT variants Leu74Val and lamivudine-selected Met184Val.

P L Sharma1, C S Crumpacker.   

Abstract

We previously showed that a didanosine-selected mutation in pNL4-3 background conferred a replication disadvantage on human immunodeficiency virus type 1, resulting in a loss of replication fitness. This work has been extended by showing that a recombinant virus with the HXBc2 backbone and reverse transcriptase (RT) fragments from pNL4-3 containing the Leu74Val mutation produce decreasing amounts of p24 antigen over a 3-week period. The HXBc2 recombinant containing the wild-type RT from pNL4-3 replicated efficiently. When the virion-associated RT containing the Leu74Val mutation was used in an RT processivity assay with homopolymer RNA template-primer, poly(A), and oligo(dT), the RT with altered Leu74Val mutation was less processive, generating fewer cDNA products in comparison to wild-type pNL4-3 RT. The replication kinetics and RT processivity of the mutant with the Leu74Val mutation were compared to those of a lamivudine-selected mutant Met184Val. In replication kinetics assays, mutant Leu74Val replicated slower than the mutant Met184Val. In a processivity assay, the mutant RTs from both viruses show comparable decreases in processivity. These observations provide biochemical evidence of decreased processivity to support the decrease in replication fitness observed with the Leu74Val or Met184Val mutations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482597      PMCID: PMC112864          DOI: 10.1128/JVI.73.10.8448-8456.1999

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

2.  Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Authors:  D R Kuritzkes; I Marschner; V A Johnson; R Bassett; J J Eron; M A Fischl; R L Murphy; K Fife; J Maenza; M E Rosandich; D Bell; K Wood; J P Sommadossi; C Pettinelli
Journal:  AIDS       Date:  1999-04-16       Impact factor: 4.177

3.  CD8+ T lymphocytes of patients with AIDS maintain normal broad cytolytic function despite the loss of human immunodeficiency virus-specific cytotoxicity.

Authors:  G Pantaleo; A De Maria; S Koenig; L Butini; B Moss; M Baseler; H C Lane; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Unusually high frequencies of HIV-specific cytotoxic T lymphocytes in humans.

Authors:  A Hoffenbach; P Langlade-Demoyen; G Dadaglio; E Vilmer; F Michel; C Mayaud; B Autran; F Plata
Journal:  J Immunol       Date:  1989-01-15       Impact factor: 5.422

5.  Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.

Authors:  D Finzi; M Hermankova; T Pierson; L M Carruth; C Buck; R E Chaisson; T C Quinn; K Chadwick; J Margolick; R Brookmeyer; J Gallant; M Markowitz; D D Ho; D D Richman; R F Siliciano
Journal:  Science       Date:  1997-11-14       Impact factor: 47.728

6.  Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.

Authors:  M H St Clair; J L Martin; G Tudor-Williams; M C Bach; C L Vavro; D M King; P Kellam; S D Kemp; B A Larder
Journal:  Science       Date:  1991-09-27       Impact factor: 47.728

7.  Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase.

Authors:  D Arion; N Kaushik; S McCormick; G Borkow; M A Parniak
Journal:  Biochemistry       Date:  1998-11-10       Impact factor: 3.162

8.  Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients.

Authors:  F Mammano; C Petit; F Clavel
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

9.  Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.

Authors:  Z Gu; Q Gao; X Li; M A Parniak; M A Wainberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

10.  Phosphorylation of 3'-azido-3'-deoxythymidine and selective interaction of the 5'-triphosphate with human immunodeficiency virus reverse transcriptase.

Authors:  P A Furman; J A Fyfe; M H St Clair; K Weinhold; J L Rideout; G A Freeman; S N Lehrman; D P Bolognesi; S Broder; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

View more
  39 in total

1.  Structural determinants of murine leukemia virus reverse transcriptase that affect the frequency of template switching.

Authors:  E S Svarovskaia; K A Delviks; C K Hwang; V K Pathak
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

2.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

Review 3.  Multiple effects of the M184V resistance mutation in the reverse transcriptase of human immunodeficiency virus type 1.

Authors:  Dan Turner; Bluma Brenner; Mark A Wainberg
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

Review 4.  Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Karidia Diallo; Matthias Götte; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

5.  Fluorescent dye terminator sequencing methods for quantitative determination of replication fitness of human immunodeficiency virus type 1 containing the codon 74 and 184 mutations in reverse transcriptase.

Authors:  Viktoria Nurpeisov; Selwyn J Hurwitz; Prem L Sharma
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

6.  Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.

Authors:  Francine Bouchonnet; Elisabeth Dam; Fabrizio Mammano; Vaea de Soultrait; Gaëlle Henneré; Henri Benech; François Clavel; Allan J Hance
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

7.  Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect.

Authors:  Lu Gao; Mark Nils Hanson; Mini Balakrishnan; Paul L Boyer; Bernard P Roques; Stephen H Hughes; Baek Kim; Robert A Bambara
Journal:  J Biol Chem       Date:  2008-01-24       Impact factor: 5.157

8.  Functional correlates of insertion mutations in the protease gene of human immunodeficiency virus type 1 isolates from patients.

Authors:  E Y Kim; M A Winters; R M Kagan; T C Merigan
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).

Authors:  Jing Lu; Prakash Sista; Françoise Giguel; Michael Greenberg; Daniel R Kuritzkes
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.

Authors:  Hong-Tao Xu; Susan P Colby-Germinario; Eugene L Asahchop; Maureen Oliveira; Matthew McCallum; Susan M Schader; Yingshan Han; Yudong Quan; Stefan G Sarafianos; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-04-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.